Zogenix Inc. (ZGNX) announced Friday morning that its Phase 3 trial of ZX008, for the treatment of Dravet syndrome, met its primary objective and demonstrated statistically significant improvements versus placebo in all key secondary measures.
from RTT - Before the Bell http://ift.tt/2wsOsKI
via IFTTT
No comments:
Post a Comment